Mankind Pharma Limited (NSE:MANKIND)

Market Cap	893.56B
Revenue (ttm)	135.46B
Net Income (ttm)	17.51B
Shares Out	412.81M
EPS (ttm)	42.63
PE Ratio	50.85
Forward PE	38.73
Dividend	2.00 (0.09%)
Ex-Dividend Date	Aug 8, 2025

Volume	128,312
Average Volume	416,467
Open	2,174.10
Previous Close	2,164.60
Day's Range	2,163.00 - 2,205.00
52-Week Range	2,090.00 - 2,998.40
Beta	0.27
RSI	44.20
Earnings Date	Jan 23, 2026

About Mankind Pharma

Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, gynaecology, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, respiratory diseases, etc. It also provides consumer healthcare products, such as condoms, pregnancy detection kits, oral contraceptives, antacid powders, vitamin a...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1991
• Employees: 26,978
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: MANKIND

Financial Performance

In 2024, Mankind Pharma's revenue was 122.07 billion, an increase of 18.98% compared to the previous year's 102.60 billion. Earnings were 19.91 billion, an increase of 4.08%.